Abstract
Abdominal aortic aneurysm (AAA) is a local expansion of the abdominal aorta wall caused by a complex multifactorial maladaptive vascular remodeling. Despite recent advances in the management of cardiovascular diseases, there currently is no established drug therapy for AAA. Since the probability of death from a ruptured AAA still remains high, preventive elective repair of AAAs larger than 5.5 cm in luminal diameter is considered the best treatment option. However, perioperative complications are problematic as elective AAA repair comes with numerous intrinsic risks. Impelled by the need of improving AAA therapy, significant efforts have been made to identify pharmacological tools that would slow down AAA enlargement and lower the risk of rupture, thereby reducing the necessity of surgical intervention. In this review, we discuss recent findings addressing molecular targets that could potentially treat AAA, particularly addressing: statins, classical renin angiotensin system (RAS) blockers, the protective arm of RAS, renin inhibitors, tetracyclines, interleukin-1β inhibition, anti-angiogenic agents and urocortins.
Keywords: Abdominal aortic aneurysm, statins, renin angiotensin system, tetracyclines, interleukin-1β.
Current Pharmaceutical Design
Title:Emerging Pharmacological Treatments to Prevent Abdominal Aortic Aneurysm Growth and Rupture
Volume: 21 Issue: 28
Author(s): Rodrigo A. Fraga-Silva, Bram Trachet and Nikolaos Stergiopulos
Affiliation:
Keywords: Abdominal aortic aneurysm, statins, renin angiotensin system, tetracyclines, interleukin-1β.
Abstract: Abdominal aortic aneurysm (AAA) is a local expansion of the abdominal aorta wall caused by a complex multifactorial maladaptive vascular remodeling. Despite recent advances in the management of cardiovascular diseases, there currently is no established drug therapy for AAA. Since the probability of death from a ruptured AAA still remains high, preventive elective repair of AAAs larger than 5.5 cm in luminal diameter is considered the best treatment option. However, perioperative complications are problematic as elective AAA repair comes with numerous intrinsic risks. Impelled by the need of improving AAA therapy, significant efforts have been made to identify pharmacological tools that would slow down AAA enlargement and lower the risk of rupture, thereby reducing the necessity of surgical intervention. In this review, we discuss recent findings addressing molecular targets that could potentially treat AAA, particularly addressing: statins, classical renin angiotensin system (RAS) blockers, the protective arm of RAS, renin inhibitors, tetracyclines, interleukin-1β inhibition, anti-angiogenic agents and urocortins.
Export Options
About this article
Cite this article as:
A. Fraga-Silva Rodrigo, Trachet Bram and Stergiopulos Nikolaos, Emerging Pharmacological Treatments to Prevent Abdominal Aortic Aneurysm Growth and Rupture, Current Pharmaceutical Design 2015; 21 (28) . https://dx.doi.org/10.2174/1381612821666150826095346
DOI https://dx.doi.org/10.2174/1381612821666150826095346 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Chymase as an Important Target for Preventing Complications of Metabolic Syndrome
Current Medicinal Chemistry Lithium and its Neuroprotective and Neurotrophic Effects: Potential Treatment for Post-Ischemic Stroke Sequelae
Current Drug Targets Pathologic Findings of Autoimmune Pancreatitis and IgG4-Related Disease
Current Immunology Reviews (Discontinued) Gadolinium-based Imaging Contrast Agents
Current Medical Imaging Identification of Candidate Biomarkers of Acute Aortic Dissection
Recent Patents on DNA & Gene Sequences Measurement of Cerebral Blood Flow with Near Infrared Spectroscopy and Indocyanine Green Dye Dilution
Current Medical Imaging The Many Antithrombotic Actions of Nitric Oxide
Current Drug Targets Therapeutic Interventions in the Glyc(oxid)ation Pathway
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Prosthetic Valve Endocarditis: Diagnostic Approach and Treatment Options
Cardiovascular & Hematological Disorders-Drug Targets Hyaluronan: The Jekyll and Hyde Molecule
Inflammation & Allergy - Drug Targets (Discontinued) Immunophilins and Cardiovascular Complications
Current Medicinal Chemistry Cyano Acrylate Polymers in Medical Applications
Recent Patents on Materials Science Disorders of Innate Immunity in Human ageing and effects of Nutraceutical Administration
Endocrine, Metabolic & Immune Disorders - Drug Targets Cardiac Remodeling Induced by Smoking: Concepts, Relevance, and Potential Mechanisms
Inflammation & Allergy - Drug Targets (Discontinued) miR-29c-3p is an Effective Biomarker of Abdominal Aortic Aneurysm in Patients Undergoing Elective Surgery
MicroRNA Free Radicals Generated by Post-Prandial Oxidative Burst in the Early Alterations of Vascular Contractility
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Role of Chymase in Preeclampsia
Current Vascular Pharmacology Mast Cells: Pivotal Players in Cardiovascular Diseases
Current Cardiology Reviews Angiogenic and Vascular Modulation by Extracellular Matrix Cleavage Products
Current Pharmaceutical Design Moderate Hypothermia in the Management of Severe Traumatic Brain Injury: A Good Idea Proved Ineffective?
Current Pharmaceutical Design